Kelly Rhoadarmer
Psychiatry · Noblesville, INNPI 1194978981
Payments from drug & device makers
Across 112 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$351
- Vanda Pharmaceuticals Inc.$288
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$264
- Otsuka America Pharmaceutical, Inc.$245
- Teva Pharmaceuticals USA, Inc.$171
- Johnson & Johnson$122
- plus $689 from 14 others
What the payments were for
- Food & beverage$2,130100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$214
How this compares
$2,130 in reported general payments places this provider in the 75th percentile of 514 psychiatry providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 29 | $240,253 |
| Austedo XrDeutetrabenazine | 26 | $201,431 |
| Invega SustennaPaliperidone Palmitate | 50 | $136,359 |
| AustedoDeutetrabenazine | 11 | $90,847 |
| RexultiBrexpiprazole | 46 | $68,797 |
| VraylarCariprazine Hcl | 39 | $59,016 |
| TrintellixVortioxetine Hydrobromide | 57 | $35,023 |
| BelsomraSuvorexant | 39 | $25,320 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 147 | $12,708 |
| Aripiprazole | 125 | $10,378 |
| Clozapine | 89 | $8,249 |
| Buspirone Hcl | 321 | $5,511 |
| Lurasidone Hcl | 45 | $5,360 |
| QuviviqDaridorexant Hcl | 11 | $5,341 |
| Paliperidone ErPaliperidone | 26 | $3,154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Loxapine | $171 | $293,64452 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $82 | $240,25329 claims |
| Johnson & JohnsonInvega Sustenna | $122 | $136,35950 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $245 | $68,79746 claims |
| AbbVieVraylar | $81 | $59,01639 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $15 | $35,02357 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $32 | $5,34111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in Noblesville
- Steven PaulCarmel$2.9M
- Jay FawverAngola$1.4M
- Suhayl NasrMichigan City$788K
- Christopher BojrabCarmel$714K
- Joseph FanelliMunster$443K
- Anantha ShekharIndianapolis$433K
- Eric JaggersJeffersonville$260K
- Larry LambertsonFort Wayne$208K
- Elizabeth MartinMarion$159K
- Leslie HulvershornIndianapolis$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.